Together with Churg–Strauss syndrome, microscopic polyarteritis ... the initial presentation of the disease. [4] Granulomatosis with polyangiitis (previously known as Wegener's granulomatosis ...

Birmingham Vasculitis Activity Scores (BVAS) were used to identify disease manifestations. Key efficacy outcomes included remission at week 26, sustained remission at week 52, relapse rates, the ...

that compared avacopan with active control regimens not including avacopan to evaluate the safety of avacopan in patients with granulomatosis with polyangiitis or microscopic polyangiitis.

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Find effective medications for 'Granulomatosis with Polyangiitis (GPA) treatment right here!' This page is a trusted source for both professionals and patients, detailing brand-name and generic ...

Rates of neutropenia, lymphopenia, and infections were lower in the patients receiving avacopan than those who were not.

1) Bell, CF., Lau, M., Shen, Q. Clinical and Economic Characteristics of Patients Diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly Churg-Strauss Syndrome) in the United ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...